Nicola Orofino

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis et al. · Blood · 2019 · 99 citations · Full text

Life Sciences, Genetics, Hematology +13

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo et al. · Oncotarget · 2015 · 67 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients

Elena Cassinerio, Nicola Orofino, Alberto Roghi et al. · Blood Cells Molecules and Diseases · 2014 · 49 citations

Medicine, Pharmacology, Pharmacotherapy +12

Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response

Alessandra Iurlo, Umberto Gianelli, Alessandro Beghini et al. · Oncotarget · 2014 · 38 citations · Full text

Medicine, Hematology, Pathology +17

Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study

Mariarita Sciumé, Nicola Orofino, Francesca Guidotti et al. · PLoS ONE · 2019 · 33 citations · Full text

Medicine, Hematology, Infectious Diseases +16